We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+49.03%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$509M
AUM Growth
+$225M
Cap. Flow
+$102M
Cap. Flow %
20.03%
Top 10 Hldgs %
100%
Holding
10
New
7
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$53.6M
2
TGTX icon
TG Therapeutics
TGTX
+$47M
3
KROS icon
Keros Therapeutics
KROS
+$33.3M
4
PCVX icon
Vaxcyte
PCVX
+$30.1M
5
CYTK icon
Cytokinetics
CYTK
+$21.7M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$69.8M
2
ARGX icon
argenx
ARGX
+$22.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMAM
1
DELISTED
Ambrx Biopharma Inc
AMAM
$238M 46.64%
16,688,636
– –
TGTX icon
2
TG Therapeutics
TGTX
$8.4B
$69.1M 13.57%
+4,046,598
New +$47M
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$1.64B
$62.8M 12.32%
+1,039,289
New +$53.6M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$50.1M 9.83%
+600,000
New +$21.7M
KROS icon
5
Keros Therapeutics
KROS
$211M
$42.2M 8.28%
+1,060,427
New +$33.3M
PCVX icon
6
Vaxcyte
PCVX
$8.12B
$36.4M 7.15%
+579,959
New +$30.1M
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$7.03M 1.38%
+192,734
New +$5.03M
NUVL
8
DELISTED
Nuvalent
NUVL
$4.25M 0.83%
+57,698
New +$3.57M
ARGX icon
9
argenx
ARGX
$53.8B
– –
-45,615
Closed -$22.4M
IMVT icon
10
Immunovant
IMVT
$8.27B
– –
-1,818,371
Closed -$69.8M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q4 2023 Portfolio in Review

As of Q4 2023, Darwin Global Management held 10 positions worth $509M, up 79% from $284M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $102M of net new capital in Q4 2023, opening 7 new positions. Its largest new stake was MoonLake Immunotherapeutics: 1,039,289 shares worth $62.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Immunovant, an estimated $69.8M sold.

  • Darwin Global Management's largest Q4 2023 buy was MoonLake Immunotherapeutics: 1,039,289 shares worth $62.8M.
  • Darwin Global Management fully exited Immunovant in Q4 2023, selling an estimated $69.8M.
  • Darwin Global Management's ten largest holdings make up 100% of its $509M portfolio in Q4 2023.
  • Darwin Global Management opened 7 new positions and closed 2 in Q4 2023.
  • Darwin Global Management's portfolio value rose 79% quarter-over-quarter to $509M.

Based on Darwin Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.